Table A2.

Sensitivity Analysis Estimating Effect of UC on HR of All-Cause Mortality After ADT Plus RT

Cohort	Prevalence of UC in ADT-Plus-RT Group	Prevalence of UC in ADT Group	UC HR	Treatment HR Adjusted for UC	95% CI
RCT cohort*
	0.20	0.40	2.00	0.73	0.69 to 0.78
	0.10	0.50	2.00	0.86	0.81 to 0.91
	0.10	0.70	2.00	0.97	0.91 to 1.04
	0.20	0.40	2.50	0.77	0.73 to 0.82
	0.10	0.50	2.50	0.96	0.90 to 1.02
	0.20	0.40	3.00	0.81	0.76 to 0.86
	0.10	0.40	3.00	0.94	0.89 to 1.01
	0.10	0.40	3.50	1.01	0.95 to 1.07
Elderly cohort†
	0.20	0.40	2.00	0.73	0.69 to 0.78
	0.10	0.50	2.00	0.86	0.81 to 0.91
	0.10	0.70	2.00	0.97	0.92 to 1.03
	0.20	0.40	2.50	0.77	0.73 to 0.82
	0.10	0.50	2.50	0.96	0.91 to 1.01
	0.20	0.40	3.00	0.81	0.77 to 0.86
	0.10	0.40	3.00	0.94	0.89 to 1.00
	0.10	0.40	3.50	1.01	0.95 to 1.07
Screen-detected cohort‡
	0.10	0.50	2.00	0.68	0.61 to 0.75
	0.10	0.70	2.00	0.77	0.69 to 0.85
	0.10	0.90	2.00	0.86	0.77 to 0.96
	0.10	0.70	2.50	0.89	0.80 to 0.99
	0.10	0.90	2.50	1.02	0.91 to 1.13
	0.10	0.50	3.00	0.83	0.74 to 0.92
	0.10	0.70	3.00	0.99	0.89 to 1.11
	0.10	0.50	3.50	0.89	0.80 to 1.00

NOTE. Bold font indicates situations where UC was strong enough to influence significance of results (ie, upper bound of 95% CI crossed 1).

Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; RCT, randomized clinical trial; RT, radiotherapy; UC, unmeasured confounder.

^*Propensity score all-cause mortality HR, 0.63; 95% CI, 0.59 to 0.67.

^†Propensity score all-cause mortality HR, 0.63; 95% CI, 0.59 to 0.67.

^‡Propensity score all-cause mortality HR, 0.50; 95% CI, 0.45 to 0.55.